FLT3 and acute myeloid leukemia: Many research groups have reported small molecule dual FLT3 and AURK inhibitors that could be beneficial for the treatment of AML; for example, barasertib developed by AstraZeneca and currently in phase II/III clinical trials [10]; CCT241736 developed by the Cancer Research UK Cancer Therapeutics Unit and currently in the preclinical stage [11]; an indolinone derivative from Chern et al. [12]; and a pyrrolopyrimidine derivative from our laboratory [13].